ERAP1 and colitis: Utilizing a previously described semi-quantitative scoring system22, we confirmed the presence of significantly (p < 0.01) increased inflammatory signs of colitis in DSS-treated ERAP1−/− mice, as compared to WT controls [Fig. 3d].